A Seamless, Phase 1b/2 Multiple Ascending Dose/Proof of Concept Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
Latest Information Update: 05 Aug 2024
At a glance
- Drugs XTMAB-16 (Primary)
- Indications Pulmonary sarcoidosis
- Focus Adverse reactions; Proof of concept
- Sponsors Xentria
- 15 Nov 2023 According to Xentria media release, the first patient being enrolled onto the study by Dr. Peter Sporn at Northwestern Memorial Hospital will add to the breadth of data that will explore the potential of XTMAB-16 in treating sarcoidosis.
- 15 Nov 2023 According to Xentria media release, Dr. Ogugua Obi is a principal investigator of this study.
- 02 Oct 2023 Planned initiation date changed from 1 Aug 2023 to 1 Oct 2023.